Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 360 entries
View as:

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Phase: N/A Priority: Normal
NCT ID: NCT00675025 Org: User:
Start: 04/04/08 End: 12/15/08 Due: 12/15/09

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Phase: N/A Priority: Normal
NCT ID: NCT00658632 Org: User:
Start: 02/29/08 End: 09/30/09 Due: 09/30/10

A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Phase: N/A Priority: Normal
NCT ID: NCT00474409 Org: User:
Start: 05/31/07 End: - Due: -

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00078637 Org: User:
Start: 01/31/04 End: 02/28/07 Due: 02/28/08

Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.

Phase: N/A Priority: Normal
NCT ID: NCT00306735 Org: User:
Start: 03/31/06 End: 12/31/07 Due: 12/31/08

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Phase: N/A Priority: Normal
NCT ID: NCT02849626 Org: User:
Start: 11/16/16 End: 12/06/21 Due: 12/06/22

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01221818 Org: User:
Start: 09/30/10 End: - Due: -

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02089412 Org: User:
Start: 02/28/14 End: 06/30/14 Due: 06/30/15

Study of E7386 in Participants With Selected Advanced Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT03264664 Org: User:
Start: 07/27/17 End: 03/31/26 Due: 03/31/27

A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy

Phase: N/A Priority: Normal
NCT ID: NCT00209573 Org: User:
Start: 09/30/04 End: 12/31/04 Due: 12/31/05

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01773421 Org: User:
Start: 06/30/11 End: 11/12/17 Due: 11/12/18

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase: N/A Priority: Normal
NCT ID: NCT02753595 Org: User:
Start: 07/13/16 End: 08/16/19 Due: 08/16/20

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Phase: N/A Priority: Normal
NCT ID: NCT01972529 Org: User:
Start: 02/28/14 End: 02/27/17 Due: 02/27/18

A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

Phase: N/A Priority: Normal
NCT ID: NCT06744673 Org: User:
Start: 01/03/25 End: 12/30/25 Due: 12/30/26

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01289509 Org: User:
Start: 12/31/10 End: 05/31/11 Due: 05/31/12

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

Phase: N/A Priority: Normal
NCT ID: NCT03054194 Org: User:
Start: 01/31/17 End: 03/02/17 Due: 03/02/18

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01136733 Org: User:
Start: 08/05/10 End: 02/08/18 Due: 02/08/19

A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion

Phase: N/A Priority: Normal
NCT ID: NCT01308541 Org: User:
Start: 01/31/11 End: 08/31/11 Due: 08/31/12

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06188559 Org: User:
Start: 04/10/24 End: 03/31/26 Due: 03/31/27

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02501096 Org: User:
Start: 07/22/15 End: 07/11/22 Due: 07/11/23

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Phase: N/A Priority: Normal
NCT ID: NCT01355289 Org: User:
Start: 11/30/11 End: 05/31/14 Due: 05/31/15

A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04231513 Org: User:
Start: 12/16/19 End: 03/09/23 Due: 03/09/24

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00121680 Org: User:
Start: 07/31/05 End: 05/31/15 Due: 05/31/16

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03583944 Org: User:
Start: 03/28/18 End: 06/28/19 Due: 06/28/20

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01221259 Org: User:
Start: 01/31/10 End: 11/30/12 Due: 11/30/13